Nov 21, 2024
Selvita Reports Significant Recovery in H2 2024, Sees Promising Outlook for the Future
Sep 10, 2020
Selvita reports strong financial results for H1 2020 and a record backlog
Jun 03, 2020
Selvita Raised Over EUR 20 Million in Its Follow-on Public Offer
May 28, 2020
The Share Issue Price in Selvita Public Offering Set at PLN 38
May 26, 2020
Selvita Extraordinary General Shareholder Meeting Decides to Proceed With the Follow-on Share Issue Initiation of the Book-building Process on Wednesday, May 27
May 26, 2020
Selvita Reports Financial Results for Q1 2020: Dynamic Increase in Backlog for 2020 and Strong Position on the Market
Apr 29, 2020
Selvita Announces Its New Development Strategy for 2020 - 2023
Mar 26, 2020
Selvita 2019 Financial Results: Accelerated Growth, 43 Percent Increase in Commercial Revenues and a Very Solid Backlog for 2020
Nov 07, 2019
Selvita Q3 2019 Results: Accelerated Growth, 45 Percent Increase in Commercial Revenues and Strong Long-term Outlook
Oct 01, 2019
Ryvu Therapeutics and Selvita Announce Registration of Corporate Split by the National Court Register of Poland
Sep 19, 2019
Selvita Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company
Sep 06, 2019
Selvita Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Sep 05, 2019
Selvita Reports Second Quarter and Half-year 2019 Financial Results
Sep 03, 2019
Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split Into Two Separately Listed Companies to Proceed
Sep 03, 2019
Selvita to Present at Upcoming Conferences in September
Jul 25, 2019
Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer
May 22, 2019
Selvita Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 13, 2019
Selvita to Present at the UBS 2019 Global Healthcare Conference in New York
Mar 28, 2019
Selvita Posts 67 Percent Increase in Operating Profit for Services Division; Innovative Research Division Reaches Inflection Point as SEL120 Enters Clinical Development
Mar 28, 2019
Selvita to Separate Oncology Therapeutics and Contract Research Business Units Into Two Global Companies